All
Global Aesthetics meeting kicks off October 28
October 1st 2015Gain an international perspective on the use of fillers and toxins, the latest advances in non-invasive techniques and technologies, and learn from a state-of-the-art practice management track that will offer business tips, marketing/branding ideas and website and social media best practices.
Isotretinoin’s discovery and development
September 17th 2015Dermatology Times editorial advisor Dr. Elaine Siegfried talks with Jim Leyden, M.D., emeritus professor of dermatology at the University of Pennsylvania about the art and science of isotretinoin therapy. Dr. Leyden, aside from being a member of the famed Acne Mafia, was a really active participant in the drug development process for isotretinoin, a drug for which, the institutional memory about that process may be fading. The two discuss many of the important initial clinical observations and those that others have made over the years.
Revolutionizing management of stage IV melanoma
September 17th 2015Accruing and forthcoming data are being looked to for guidance on the best strategies for implementing these treatments. As valued members of the multidisciplinary care team for patients with metastatic melanoma, dermatologists should keep informed about these topics.
Managing severe pediatric atopic dermatitis
September 10th 2015Older non-specific immunomodulatory drugs and off-label use of several biologic agents offer treatment options for children with severe atopic dermatitis (AD). However, the future should bring therapies specifically developed for treatment of AD investigated in children.
Quality of life impact of anticancer drugs
September 9th 2015The development of novel targeted anticancer therapies are proving to have a significant impact in the treatment and management of cancer patients; however, these agents also are associated with a distinct set of cutaneous side effects. Learn more.
Step therapy stalls appropriate patient treatment
August 19th 2015Step therapy policies place a large administrative burden on physicians, which, in turn, takes time away from patient care. Some states are working on legislation that seeks to regulate step therapy protocols and ensure they are safe for patients.